## Abstract An antiserum which is able to inhibit TAF‐induced neovascularization in vivo(TAF antiserum) was used to develop two quantitative assays for TAF‐containing tumour extracts (tumor TAF).I) Radioimmunometric assay (RIMA): the IgG of the TAF antiserum was labelled with ^125^I. An excess of ^
Tumour angiogenesis factor (TAF) and its neutralisation by a xenogeneic antiserum
✍ Scribed by Paul Phillips; Shant Kumar
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- French
- Weight
- 626 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Tumour angiogenesis factor (TAF) has been extracted from a variety of animal and human tumours. Its ability to induce neovascularization in two bioassays, viz. rat air‐sac and chick chorio‐allantoic membrane, is demonstrated. Similar extracts from normal tissues fail to induce angiogenesis. TAF extracts have been used to raise a xenogeneic antiserum, the specificity of which was investigated using classical immunological methods. Its ability to neutralize the biological activity of TAF using the two in vivo assays, was also demonstrated.
📜 SIMILAR VOLUMES
## Abstract Tumour extracts were obtained from rat Walker 256 carcinoma and examined for the presence of tumour angiogenesis factor (TAF) __in vivo__ before being used in tissue culture experiments. Capillary endothelial cells derived from cow brain white matter were used to study the effects of TA